The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

Intravenous immunoglobulin (IVIg) therapy has been suggested as a potential treatment
option for hospitalised COVID‐19 patients. The aim of this systematic review and meta …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a huge obstacle
to the health system due to the high rate of contagion. It is postulated that intravenous …

The development of therapies for SARS-CoV-2 infection, based on virus biology and
pathology, and of large-and small-scale randomized controlled trials, have brought forward …

This review is focused on the use of hyperimmune globulin therapy to treat some infectious
diseases of viral or bacterial origin. Despite the introduction of antibiotics and vaccines …

Background The clinical benefits of high-dose intravenous immunoglobulin (IVIg) in treating
COVID-19 remained controversial. Methods We systematically searched databases up to …

Abstract Coronavirus disease 2019 (COVID-19) is a viral disease caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), a member of the Coronaviridae family …

Background The clinical efficacy and safety of intravenous immunoglobulin (IVIg) treatment
for COVID-19 remain controversial. This study aimed to map the current status and gaps of …

Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) caused a pandemic named coronavirus disease 2019 (COVID-19) that has become …

We wanted to evaluate the efficacy of intravenous immunoglobulin (IVIG) treatment in Covid-
19 patients in the intensive care unit (ICU). Sixteen (66.7%) male and 8 (33.3%) female adult …